Synergistic interaction between oncolytic viruses augments tumor killing.
A major barrier to all oncolytic viruses (OVs) in clinical development is cellular innate immunity, which is variably active in a spectrum of human malignancies. To overcome the heterogeneity of tumor response, we combined complementary OVs that attack cancers in distinct ways to improve therapeutic outcome. Two genetically distinct viruses, vesicular stomatitis virus (VSV) and vaccinia virus (VV), were used to eliminate the risk of recombination. The combination was tested in a variety of tumor types in vitro, in immunodeficient and immunocompetent mouse tumor models, and ex vivo, in a panel of primary human cancer samples. We found that VV synergistically enhanced VSV antitumor activity, dependent in large part on the activity of the VV B18R gene product. A recombinant version of VSV expressing the fusion-associated small-transmembrane (p14FAST) protein also further enhanced the ability of VV to spread through an infected monolayer, resulting in a "ping pong" oncolytic effect wherein each virus enhanced the ability of the other to replicate and/or spread in tumor cells. Our strategy is the first example where OVs are rationally combined to utilize attributes of different OVs to overcome the heterogeneity of malignancies and demonstrates the feasibility of combining complementary OVs to improve therapeutic outcome.
Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Fabrice
F
Le Boeuf
Jean-Simon
JS
Diallo
J Andrea
JA
McCart
Steve
S
Thorne
Theresa
T
Falls
Marianne
M
Stanford
Femina
F
Kanji
Rebecca
R
Auer
Christopher W
CW
Brown
Brian D
BD
Lichty
Kelley
K
Parato
Harold
H
Atkins
David
D
Kirn
John C
JC
Bell
D000818:Animals; D002522:Chlorocebus aethiops; D005260:Female; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods; D005822:Genetic Vectors / Q000235:genetics; D019073:HT29 Cells; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000009:adverse effects* / Q000379:methods*; D050504:Oncolytic Viruses / Q000235:genetics / Q000502:physiology*; D014616:Vaccinia virus / Q000235:genetics / Q000502:physiology; D014709:Vero Cells; D018116:Vesiculovirus / Q000235:genetics / Q000502:physiology